公开(公告)号：US20180140582A1

公开(公告)日：2018-05-24

申请号：US15876619

申请日：2018-01-22

Applicant: NOVARTIS AG

Inventor： Jun CAO ,  Bernhard ERB ,  Robin Alec FAIRHURST ,  Arnaud GRANDEURY ,  Shinji HATAKEYAMA ,  Magdalena KOZICZAK-HOLBRO ,  Xinzhong LAI ,  Philipp LUSTENBERGER ,  Bernd Ulrich RIEBESEHL ,  Nicola TUFILLI ,  Thomas ULLRICH ,  Xiang WU ,  Jianguang ZHOU

IPC: A61K31/428 ,  C07C53/10 ,  C07D277/68 ,  A61K45/06 ,  A61K31/167

CPC classification number: A61K31/428 ,  A61K31/167 ,  A61K45/06 ,  C07B2200/07 ,  C07C53/10 ,  C07D277/68 ,  Y02P20/55

Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.

公开(公告)号：US20180273522A1

公开(公告)日：2018-09-27

申请号：US15762724

申请日：2016-09-20

Applicant: Novartis AG

Inventor： Eric AUBIN ,  Anthony CASAREZ ,  Andreas FISCH ,  Zaixing LI ,  Mika LINDVALL ,  Heinz Ernst MOSER ,  Michael MUTZ ,  Folkert RECK ,  Bernd Ulrich RIEBESEHL ,  Marc SCHOENHENTZ ,  Vijay SETHURAMAN ,  Robert Lowell SIMMONS

IPC: C07D417/14 ,  A61P31/04

CPC classification number: C07D417/14 ,  A61P31/04 ,  C07B2200/13

Abstract: The invention provides new solid forms, salts and polymorphs of 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (referred to herein as Compound X), pharmaceutical compositions containing them, and processes for their manufacture and use in therapy.